Newborn Screening Programmes

Parsons, Evelyn; Bradley, Don M.

doi:10.1002/9780470015902.a0005637.pub2

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less seems to be written about the child and who protects his or her right to a healthy life. Different arguments based on a public health versus a genetics approach are possible [4].…”

Section: Population Screeningmentioning

confidence: 99%

Public Health, Communicable Diseases and Global Health

Trent

2012

Molecular Medicine

View full text Add to dashboard Cite

“…Less seems to be written about the child and who protects his or her right to a healthy life. Different arguments based on a public health versus a genetics approach are possible [4].…”

Section: Population Screeningmentioning

confidence: 99%

Public Health, Communicable Diseases and Global Health

Trent

2012

Molecular Medicine

View full text Add to dashboard Cite

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Forman¹,

Coyle²,

Levy-Fisch³

et al. 2012

J Community Genet

View full text Add to dashboard Cite

Newborn metabolic screening is the most widespread application of screening technology and provides the most comprehensive application of genetics in health services, where the Guthrie blood spot cards allow screening for metabolic diseases in close to 100 % of all newborn babies. Despite over 40 years of use and significant benefits to well in excess of 100,000 children worldwide, there is remarkably little consensus in what conditions should be screened for and response to new advances in medicine relating to programme expansion. In this article, the international criteria for newborn metabolic screening are considered, and we propose that these criteria are poorly developed in relation to the baby, its family and society as a whole. Additionally, the ethical issues that should inform the application of screening criteria are often not developed to a level where a consensus might easily be achieved. We also consider that when family interests are factored in to the decision-making process, they have a significant influence in determining the list of diseases in the panel, with countries or states incorporating family and societal values being the most responsive. Based on our analysis, we propose that decision criteria for metabolic screening in the newborn period should be adapted to specifically include parent and family interests, community values, patients’ rights, duties of government and healthcare providers, and ethical arguments for action in the face of uncertainty.

show abstract

Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7

et al. 2008

View full text Add to dashboard Cite

Early results from the National Health Service Sickle Cell and Thalassaemia Screening programme covering the whole of England are reported following the implementation of the national newborn blood-spot screening programme. Of the 13 laboratories performing screening, 10 chose high-performance liquid chromatography as the first screen, with isoelectric focusing as the second confirmatory test. Screening results for

show abstract

Newborn Screening Programmes

Cited by 4 publications

References 14 publications

Public Health, Communicable Diseases and Global Health

Public Health, Communicable Diseases and Global Health

Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening

Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7

Contact Info

Product

Resources

About